| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.095 | 0.1 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |